According to market observers, shares of the company are available at a premium of ₹101 in the grey market today ...

By Kashish Tandon (Reuters) -Indian drugmaker Anthem Biosciences' [ANTH.NS] $395 million IPO was fully subscribed on the ...

The Rs 3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, the Bangalore-based contract research, development, ...

Among investor categories, Non-Institutional Investors (NIIs) have shown the highest interest, bidding 1.55 times their ...

With a unique business model rooted in innovation-led drug development services, the company is betting big on global ...

Anthem ticks all the boxes. But with lofty valuations and limited margin headroom, analysts warn the IPO may not deliver ...

Anthem Biosciences' IPO witnessed strong investor interest, being oversubscribed 2.08 times on Day 2, driven by NIIs.

Anthem Biosciences' initial share sale received bids for 14,47,66,596 shares, as against 4,40,70,682 shares on offer, ...

The mainline issue will close for public subscription on Wednesday, July 16. The basis of allotment of shares is likely to be ...

Anthem Biosciences raised ₹1,016.02 crore from 60 institutional investors ahead of its IPO launch on July 14. The offering, ...

Indian drugmaker Anthem Biosciences' ANTH.NS $395 million public listing was fully subscribed on the second day of bidding, as investors bet on the company's growth prospects at a time when global big ...

Anthem Biosciences, ₹3,395 crore IPO was fully subscribed by Day 2, with strong interest from non-institutional investors, ...